An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009370/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety, tolerability, and dose regimen of
daratumumab when administered in combination with various treatment regimens for the
treatment of multiple myeloma.
提供机构：
Vivli
创建时间：
2023-10-17
